Savara’s (SVRA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research note released on Monday, Benzinga reports. JMP Securities currently has a $9.00 price target on the stock.

A number of other research analysts have also weighed in on the company. Evercore ISI cut their price objective on Savara from $10.00 to $7.00 and set an outperform rating on the stock in a report on Thursday, May 16th. HC Wainwright reiterated a buy rating and issued a $10.00 price target on shares of Savara in a report on Wednesday, August 14th. Guggenheim lifted their price objective on Savara from $8.00 to $10.00 and gave the company a buy rating in a research note on Thursday, June 27th. Finally, Oppenheimer upped their target price on Savara from $11.00 to $15.00 and gave the stock an outperform rating in a research note on Wednesday, June 26th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of Buy and an average target price of $11.17.

Savara Price Performance

Shares of SVRA stock opened at $4.32 on Monday. The firm has a market capitalization of $711.07 million, a price-to-earnings ratio of -11.68 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. The stock’s 50-day simple moving average is $4.43 and its 200-day simple moving average is $4.54. Savara has a fifty-two week low of $3.12 and a fifty-two week high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, equities analysts forecast that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Institutional investors have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co acquired a new stake in Savara during the 1st quarter worth $35,000. Choreo LLC acquired a new position in Savara during the second quarter worth about $59,000. DRW Securities LLC purchased a new stake in Savara during the 2nd quarter valued at about $62,000. Principal Financial Group Inc. raised its holdings in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the last quarter. Finally, Profund Advisors LLC purchased a new position in Savara in the 2nd quarter worth approximately $105,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.